Genovese MC, et al. - Experts evaluated the long-term safety and effectiveness of ixekizumab, an IL-17A antagonist, in patients with active PsA. Ixekizumab remained consistent in overall safety profile during the extension period as that observed with the double-blind period. The clinical improvements of ixekizumab were seen to persist up to 1 year. As measured by ACR responses at week 52, efficacy was demonstrated by the placebo patients re-randomized to ixekizumab.